{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T20:48:14Z","timestamp":1764362894742},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,12,7]],"date-time":"2007-12-07T00:00:00Z","timestamp":1196985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\n\t\t\t\t\t<\/jats:bold> Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollens is a major problem in Japan. Omalizumab, a humanized monoclonal anti\u2010IgE antibody, improves symptoms associated with SAR, but a comparative study with an anti\u2010allergy drug has not yet been conducted.<\/jats:p><jats:p><jats:bold>Objective\n\t\t\t\t\t<\/jats:bold> To compare the efficacy and safety of omalizumab with suplatast tosilate, a selective T\u2010helper type 2 (Th2) cytokine inhibitor, in patients with Japanese cedar pollen\u2010induced SAR.<\/jats:p><jats:p><jats:bold>Methods\n\t\t\t\t\t<\/jats:bold> A randomized, double\u2010blind, double\u2010dummy study was conducted in 308 Japanese patients with a history of moderate\u2010to\u2010severe SAR who showed a CAP\u2010RAST value (2+) specifically to Japanese cedar pollens. Patients were treated for 12 weeks with omalizumab plus placebo of suplatast tosilate or suplatast tosilate plus placebo of omalizumab.<\/jats:p><jats:p><jats:bold>Results\n\t\t\t\t\t<\/jats:bold> The mean daily nasal symptom medication scores (sum of the daily nasal symptom severity score and daily nasal rescue medication score) were significantly lower in the omalizumab group than in the suplatast tosilate group during three evaluation periods (<jats:italic>P<\/jats:italic>&lt;0.001). The omalizumab group also had significantly lower mean daily nasal severity scores, each of the mean daily nasal and ocular symptom severity scores (sneezing, runny nose, stuffy nose, itchy nose, itchy eyes, watery eyes, and red eyes). Omalizumab reduced rescue medication requirements, and the proportion of days with any rescue medication use in the omalizumab group was significantly lower. Serum\u2010free IgE levels markedly decreased in the omalizumab group and it was associated with clinical efficacy. The adverse reaction profiles were similar between the two groups. The overall incidence of injection site reactions was higher in the omalizumab group than in the suplatast tosilate group, but all these events were of mild degree. No anti\u2010omalizumab antibodies were detected.<\/jats:p><jats:p><jats:bold>Conclusion\n\t\t\t\t\t<\/jats:bold> Omalizumab showed significantly greater improvements than suplatast tosilate in the treatment of SAR induced by Japanese cedar pollens.<\/jats:p>","DOI":"10.1111\/j.1365-2222.2007.02894.x","type":"journal-article","created":{"date-parts":[[2010,8,3]],"date-time":"2010-08-03T10:37:41Z","timestamp":1280831861000},"page":"329-337","source":"Crossref","is-referenced-by-count":41,"title":["Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen\u2010induced seasonal allergic rhinitis"],"prefix":"10.1111","volume":"38","author":[{"given":"T.","family":"Nagakura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,12,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63532-6"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000083322"},{"key":"e_1_2_5_4_2","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.151.5.2623","article-title":"Humanization of an antibody directed against IgE","volume":"151","author":"Presta LG","year":"1993","journal-title":"J Immunol"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000237010"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.06.032"},{"key":"e_1_2_5_7_2","first-page":"1303","article-title":"Central role of immunoglobulin (Ig) E in the reduction of lung eosinophil infiltration and T helper 2 cell cytokine production","volume":"183","author":"Coyle AJ","year":"1996","journal-title":"inhibition by a non-anaphylactogenic anti-IgE antibody"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000070434"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.128804"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01180.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.125488"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200312-1651OC"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.02.028"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.55.379"},{"key":"e_1_2_5_15_2","first-page":"273","article-title":"Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid\u2010dependent asthma","volume":"356","author":"Tamaoki J","year":"2000","journal-title":"a double-blind randomised study"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/194589240201600609"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62611-7"},{"key":"e_1_2_5_18_2","volume-title":"Clinical guideline for allergic rhinitis in Japan. Perennial and seasonal allergic rhinitis","author":"Establishment Committee of the Clinical Guideline for Allergic Rhinitis.","year":"2002"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(99)00303-3"},{"key":"e_1_2_5_20_2","first-page":"369","article-title":"Ipd\u20101151t","volume":"34","author":"Koda A","year":"1991","journal-title":"a prototype drug for IgE antibody synthesis modulation"},{"key":"e_1_2_5_21_2","first-page":"31","article-title":"Suppression of IgE production by IPD\u20101151T (suplatast tosilate), a new dimethylsulfonium agent","volume":"61","author":"Yanagihara Y","year":"1993","journal-title":"(2). Regulation of human IgE response"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1415"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.112.3.862-a"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199406093302307"},{"key":"e_1_2_5_25_2","first-page":"521","article-title":"Mechanism of topical glucocorticoid treatment of hay fever","volume":"106","author":"Kita H","year":"2000","journal-title":"IL-5 and eosinophil activation during natural allergen exposure are supressed, but IL-4, IL-6, and IgE antibody production are unaffected"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(77)90156-7"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2001.01202.x"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2005.06.008"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)70202-1"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.11.053"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.10.003"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2006.02616.x"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2002.01547.x"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)90151-1"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.108310"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62171-0"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.09.036"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.121949"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.118891"},{"key":"e_1_2_5_40_2","first-page":"709","article-title":"Efficacy and tolerability of anti\u2010immunoglobulin E therapy with omalizumab in patient with concomitant allergic asthma and persistent allergic rhinitis","volume":"59","author":"Vignola AM","year":"2004","journal-title":"SOLAR"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2222.2007.02894.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2222.2007.02894.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T22:10:19Z","timestamp":1697235019000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2222.2007.02894.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,7]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1111\/j.1365-2222.2007.02894.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2222.2007.02894.x","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,7]]}}}